# Central Nervous System (CNS) Agents: Narcolepsy

**LENGTH OF AUTHORIZATIONS**: 365 Days

**PRIOR AUTHORIZATION CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval

- Contraindications to or drug interaction with medications not requiring prior approval

- History of unacceptable/toxic side effects to medications not requiring prior approval

**NON-PREFERRED MEDICATION:**

- For non‐preferred drugs without medication specific criteria, there must have been an inadequate clinical response to preferred alternatives, including a trial of no less than 30 days each of at least two preferred products

**PRIOR AUTHORIZATION CRITERIA:**

- Sunosi (soriamfetol)

  - Diagnosis of narcolepsy with excessive daytime sleepiness or obstructive sleep apnea with excessive daytime sleepiness **AND**
  - An inadequate response to or inability to tolerate a 30-day course of treatment with modafinil or armodafinil **AND**
  - An inadequate response to or inability to tolerate a 30-day course of treatment with a preferred methylphenidate or amphetamine product

- Wakix (pitolisant), Xyrem (sodium oxybate)

  - Diagnosis of narcolepsy with excessive daytime sleepiness **AND**
  - An inadequate response to or inability to tolerate a 30‐day course of treatment with modafinil or armodafinil **AND**
  - An inadequate response to or inability to tolerate a 30‐day course of treatment with a preferred methylphenidate or amphetamine product **OR**
  - Diagnosis of narcolepsy with cataplexy

- Xywav (calcium, magnesium, potassium & sodium oxybates)

  - Diagnosis of narcolepsy with excessive daytime sleepiness **AND**
  - An inadequate response to or inability to tolerate a 30‐day course of treatment with modafinil or armodafinil **AND**
  - An inadequate response to or inability to tolerate a 30‐day course of treatment with a preferred methylphenidate or amphetamine product **AND**
  - Sodium restriction with documented adherence to sodium restricted diet **OR**
  - Diagnosis of narcolepsy with cataplexy **AND**
  - Sodium restriction with documented adherence to sodium restricted diet

**REAUTHORIZATION CRITERIA:**

Attestation that the patient’s condition has improved while taking the requested medication

## Narcolepsy

| Central Nervous System (CNS) Agents: Narcolepsy    |                           |
|----------------------------------------------------|---------------------------|
| PREFERRED                                          | NON-PREFERRED             |
| Amphetamine/Dextroamphetamine                      | Sunosi                    |
| Armodafinil                                        | Wakix                     |
| Dextroamphetamine ER                               | Xyrem                     |
| Methylphenidate ER                                 | Xywav                     |
| Methylphenidate Tab                                |                           |
| Modafinil                                          |                           |

**Link to Criteria:** [Central Nervous System (CNS) Agents: Narcolepsy](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220415_UPDL_Criteria_FINAL_.pdf#page=38)
